VNRX Form 4: CEO Jasmine Kway Awarded 12,507 RSUs (Aug 15, 2025)
VolitionRX Limited director and CEO - Singapore Jasmine Kway was granted 12,507 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation.
Rhea-AI Filing Summary
VolitionRX Limited director and CEO - Singapore Jasmine Kway was granted 12,507 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two installments of 6,254 RSUs on 11/01/2025 and 6,253 RSUs on 02/01/2026. Upon vesting and settlement, each vested RSU converts into one share of common stock. Following the award, the reporting person beneficially owns 203,614 shares, with 10,400 shares held indirectly by spouse.
Positive
- Cash conservation: RSUs were issued in lieu of cash compensation, preserving corporate cash resources
- Retention-focused vesting: Monthly earning plus two time-based vesting dates encourage continued service through Feb 1, 2026
- Transparent disclosure: Form 4 clearly states award size, earning schedule, vesting dates, and indirect spouse ownership
Negative
- Dilution: Grant of 12,507 RSUs will increase outstanding shares upon settlement, diluting existing shareholders
- Delayed value realization: The executive must satisfy earning and vesting conditions before receiving shares, which could be forfeited if service ends
Insights
TL;DR Awarded 12,507 RSUs in lieu of cash; phased earning and vesting reduces immediate dilution and aligns pay with shareholder outcomes.
Issuing RSUs instead of cash preserves corporate cash while providing the CEO with equity-linked compensation that vests over time. The structure—monthly earning followed by two time-based vesting dates—ties near-term service to eventual share delivery and can help retain the executive through early 2026. The reported beneficial ownership of 203,614 shares (including 10,400 indirectly) gives context to the executive's stake but does not indicate a material shift in control.
TL;DR Standard equity-based compensation disclosure; schedule and spouse-held shares are clearly reported.
The Form 4 provides transparent details on the RSU grant mechanics and vesting schedule, meeting Section 16 reporting expectations. The two-tier vesting after earning suggests retention-focused design. Indirect ownership via spouse is disclosed, which is important for assessing aggregate insider holdings. No amendments or atypical derivative transactions are reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 12,507 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. On August 15, 2025, the reporting person was awarded 12,507 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two installments of 6,254 units and 6,253 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Jasmine Kway report on Form 4 for VNRX?
When do the RSUs begin to be earned and when do they vest?
Were any derivative securities reported?
Why were RSUs issued instead of cash?
AI-generated analysis. How Rhea-AI works. Not financial advice.